AN2 Therapeutics, Inc. Common Stock

ANTXNASDAQ • USD
ThemeBiotech - Drug Development›Infectious Disease & Vaccines
5.07 USD
↘ 0.54 (9.63%)AT CLOSE (03:59 PM EDT)
5.07
↘ 0.00 (0.10%)
POST MARKET (AS OF 05:19 PM EDT)
Post Market
AS OF 05:19 PM EDT
5.07
↘ 0.00 (0.10%)
🟢Market: OPEN

Shares of AN2 Therapeutics, Inc. Common Stock (ANTX) are trading at $5.07. Technicals currently rate "Neutral" while our fundamental analysis reads "Neutral". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation side, ANTX appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Oct 6, 2026.

Open?$5.39
High?$5.60
Low?$5.01
Prev. Close?$5.61
Volume?318.2K
Avg. Volume?250.1K
VWAP?$5.17
Rel. Volume?1.27x
Bid / Ask
Bid?$4.30 × 100
Ask?$6.01 × 100
Spread?$1.71
Midpoint?$5.15
Valuation & Ratios
Market Cap?211.7M
Shares Out?37.7M
Float?25.1M
Float %?69.7%
P/E Ratio?N/A
P/B Ratio?2.79
EPS?-$0.96
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
Themes
Biotech - Drug Development›Infectious Disease & VaccinesBiotech - Drug Development›Rare Disease Therapeutics
Employees
21
Market Cap
211.7M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.an2therapeutics.com
Listed
2022-03-25
Address
1300 EL CAMINO REAL, SUITE 100
MENLO PARK, CA 94025
Phone: (650) 331-9090
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
28
Piotroski F-Score?0/9Weak
Altman Z-Score?17.15Safe
Confidence?43%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?9.56%Elevated
Short Interest?2.4M
Days to Cover?11.8
Free Float25.1M
Avg Daily Volume203.3K
Settlement Date2026-09-15
Financial Health
Current Ratio?14.32Strong
Quick Ratio?14.32Strong
Cash Ratio?7.94Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
59
2.79CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-4.3CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-47.8%WEAK▾
ROA?
S&P
3
-44.4%WEAK▾
Cash Flow & Enterprise
FCF?$-30682000
Enterprise Value?$167.4M
Fundamentals ratios updated end of day
MarketsMoversWatchlist